Congenital pulmonary vein stenosis (PVS) is a rare condition, resulting from abnormal incorporation of the common pulmonary vein into the left atrium. (1) (2) (3) One or more of the 4 pulmonary veins may be involved and it is commonly associated with other congenital heart defects (CHD), but can occur in isolation. (2) (3) (4) Commonly, patients present with respiratory symptoms with varying degrees of pulmonary hypertension. (5, 6) Surgical results are generally poor with a high risk of recurrence and high mortality.
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RESULTS
Five patients with congenital PVS were identified; congenital PVS accounted for 0.0007% of all CHD (5 out of 7 345 cases) seen at our institution during the same time period.
Three of the 5 patients were females and the age at diagnosis ranged from 22 months -13 years. All cases of PVS were unilateral and right-sided and were associated with other CHD ( Table 1 ).
Four of the 5 patients presented with respiratory distress, with one patient diagnosed incidentally during cardiac catheterisation undertaken to investigate the cause of pulmonary hypertension.
The other presenting symptom was haemoptysis in 2 of the 5 patients. All the patients had invasive cardiac catheterisation, which assisted in the diagnosis or confirmation of PVS. All were found to have pulmonary hypertension with mean pulmonary artery pressure (PAP) exceeding 25mmHg and all were also noted to have elevated pulmonary artery wedge pressures on the ipsilateral side of the PVS ( Table 2 ). Of note, there was no elevation of oxygen saturations in the affected ipsilateral pulmonary artery, which can be associated with PVS as outlined in the discussion below. As part of management, all the patients underwent corrective surgery for the associated CHD. Case 1 was referred for cardiac assessment at the age of 10 months when she presented with shortness of breath and was noted to have a cardiac murmur. She underwent cardiac catheterisation for assessment of VSD and was found to have right upper and lower PVS. She had surgical closure of the VSD and widening of the pulmonary veins using a pericardial patch at the age of 12 months. She remained asymptomatic following the surgery but presented at the age of 10 years with respiratory distress and chest pain. She was found to have a heart defects of 0.03% (31 of 98 126). (6) Congenital PVS is thought to result from abnormal incorporation of the common pulmonary vein into the left atrium. (1) (2) (3) One or more of the 4 pulmonary veins may be involved, and may be unilateral on the left or right or bilateral and involve either lung. (1) (2) (3) (4) (5) All the cases of PVS in our study were unilateral and right sided, and only one or 2 pulmonary veins were an older age, (8) which may be the reason for the later presentation and diagnosis in our patients -all of whom had involvement of 1 -2 pulmonary veins (Table 1) . Congenital PVS is caused by a progressive neoproliferative process and may not be present at birth. (2, 3) It is also possible that the study patients have a more benign disease process, which progresses more slowly, and hence the late presentation and diagnosis.
The incidence of associated congenital heart defects in patients with congenital PVS ranges from 30% -80%. (2, 3) We have reported a higher incidence of associated CHDs with 100% of our patients having one or more associated CHDs.
All patients were found to have mildly elevated pulmonary artery pressures, associated with markedly increased pulmonary capillary wedge pressures on the affected side ( Table 2) (Table 1) , the latter physiological feature was not observed.
PVS is associated with significant morbidity and mortality, with a less than 50% 5-year survival. (3, 7, 8) Although the small cohort of 5 patients, and the high level of loss to follow-up limit our and patch anastomosis to enlarge the tightened segment). (1, 9, 10) A new surgical strategy called sutureless marsupialisation where the pericardium surrounding the affected PV is directly attached to the LA, so direct stiches over the cut edges of the vessel are avoided, has been used. (9) (10) (11) Pneumonectomy such as in case 2, may be necessary for patients with haemoptysis, while those with unrelenting progression and development of severe pulmonary hypertension, are managed with lung transplantation. (2, 10) Overall, surgical outcomes have been disappointing. The condition is generally unresponsive to treatment and tends to recur. (4, 7, 10) Transcatheter interventions include the use of stents and balloon dilatation. (2, 10, 11) There are, however, poor outcomes with these interventions and limited experience of percutaneous interventions in children. (2, 10, 12) A recent study by Callahan, et al. explored the use of adjunct targeted biologic inhibition agents to treat paediatric PVS. (13) Histologic series have identified fibroblasts and myofibroblastlike cells as significant contributors to the mesenchymal proliferation that is a hallmark of pulmonary vein stenosis pathophysiology. (2, 14) Callahan, et al. evaluated the use of imatinib mesylate with or without bevacizumab targeting neoproliferative myofibroblast-like cells with tyrosine kinase receptor expression, as adjuncts to modern interventional therapies for the treatment of multivessel intraluminal pulmonary vein stenosis. (13) The results of the study were inconclusive with a major confounding factor being the use of other conventional management of the PVS during the study period. The role of these agents needs further evaluation.
CONCLUSION
This is first case series report of congenital PVS in an African setting. We have confirmed that congenital PVS is a rare condition and that all cases were associated with other Conflict of interest: none declared.
